3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
8
Triple Negative Breast Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
5
Urinary Bladder Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Pathologic Complete Response
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
Paclitaxel
3
Doxorubicin
3
Cyclophosphamide
3
Trastuzumab
2
Surgical Procedures, Operative
2
Carboplatin
2
pertuzumab
1
liposomal doxorubicin
1
cemiplimab
1
atezolizumab
1
Radiotherapy
1
Magnetic Resonance Spectroscopy
1
Lapatinib
1
Indocyanine Green
1
Anastrozole
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Invasive Breast Cancer
×
cemiplimab
×
Breast
×
Clear all
NCT04243616
2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2
Active not recruiting
36 enrolled